Cover Picture: The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R,2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer (ChemMedChem 7/2013)

Citations Over TimeTop 19% of 2013 papers

Abstract

Graphical Abstract The front cover picture shows the pan-cyclin-dependent kinase (CDK) inhibitor BAY 1000394 embedded in a schematic depiction of the cell cycle and a colored paraffin section of an untreated A2780Cis ovarian cancer tumor grown on a nude mouse. Aminopyrimdine BAY 1000394 is a balanced, orally available pan-CDK inhibitor with potent, broad-spectrum antiproliferative activity against human cancer cell lines, and is currently being investigated in a phase I clinical trial in patients with advanced solid tumors. For more details, see the Full Paper by Ulrich Lücking et al. on p. 1067 ff.

Related Papers

• → Development of selective mono or dual PROTAC degrader probe of CDK isoforms(2019)106 cited
• → Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines(2009)13 cited
• → Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.(1995)963 cited
• → Data from Expression levels of p18<sup>INK4C</sup> modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines(2023)
• → Data from Expression levels of p18<sup>INK4C</sup> modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines(2023)